proteins initiates rapid repair of injured tissue without the need for invasive surgical procedures. TissueGene is currently developing four product candidates, TG-C, TG-B, TG-D, and TG-N for the regeneration of cartilage, bone, disc, and nerve, respectively. The company's lead product candidate, TG-C, has been developed for treating osteoarthritis of the knee and is currently in Phase II trials in the US and in Phase III trials in Korea.